Ask AI
ProCE Banner Activity

Emerging DLL3-Targeted Therapies for Extrapulmonary Neuroendocrine Carcinomas

Podcast Episodes

Listen to Dr. Daniel Morgensztern and Dr. Jonathan Strosberg discuss the diagnosis, prognosis, and current limited treatment options for poorly differentiated extrapulmonary neuroendocrine carcinomas, followed by a discussion focusing on emerging DLL3-targeted therapies, including bispecific therapies, antibody–drug conjugates, and CAR T-cell therapies, and their potential roles in improving patient outcomes.

Released: August 15, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Boehringer Ingelheim Pharmaceuticals, Inc.

Disclosure

Primary Author

Daniel Morgensztern, MD: consultant/advisor/speaker: AbbVie, Arcus, Bayer, Bristol Myers Squibb, Johnson & Johnson, Lilly, Mirati, Natera, Tubulis; researcher: AbbVie, AstraZeneca, Bristol Myers Squibb, Celgene, EpicentRx, Incyte, Merck, Pfizer, Roche.

Jonathan Strosberg, MD: consultant/advisor/speaker: Boehringer Ingelheim, Curium, Exelixis.